A phase II study of alisertib (MLN8237) in recurrent or persistent uterine leiomyosarcoma: An NRG Oncology/Gynecologic Oncology Group Study (GOG-0231D) Meeting Abstract

  


Authors: Hyman, D. M.; Sill, M.; Cho, J. K.; Lankes, H. A.; Piekarz, R.; Hensley, M. L.
Abstract Title: A phase II study of alisertib (MLN8237) in recurrent or persistent uterine leiomyosarcoma: An NRG Oncology/Gynecologic Oncology Group Study (GOG-0231D)
Meeting Title: 51st Annual Meeting of the American Society of Clinical Oncology (ASCO)
Journal Title: Journal of Clinical Oncology
Volume: 33
Issue: 15 Suppl.
Meeting Dates: 2015 May 29-Jun 2
Meeting Location: Chicago, IL
ISSN: 0732-183X
Publisher: American Society of Clinical Oncology  
Date Published: 2015-05-20
Language: English
ACCESSION: WOS:000358036903309
PROVIDER: wos
DOI: 10.1200/jco.2015.33.15_suppl.e16512
Notes: Meeting Abstract: e16512 -- Source: Wos
Altmetric
What is Altmetric?
Citation Impact
What is Dimensions Citation Badge?
BMJ Impact Analytics
MSK Authors
  1. Martee L Hensley
    289 Hensley
  2. David Hyman
    354 Hyman
Related MSK Work